Insights - Spring Bank provided a business update earlier this week to discuss 2019 development plant for their immune-modulator inarigivir in treating Hepatitis B. Although the company also discussed … Continue Reading
Premium: Read NowInsights - Fennec announced some bad news this morning. Their NDA submission for Pedmark has been pushed back by 9-12 months to “late 2019 to early 2020”. The NDA … Continue Reading
Read NowInsights - This morning, Aldeyra hosted their R&D day, where they discussed their pipeline and upcoming plans. Although no AC data was reported, the company did give color … Continue Reading
Read NowInsights - It seems the market is starting to realize Bellus’ potential as the company touched a 52 week high today on the Canadian listing when it … Continue Reading
Read NowInsights - Today Fennec (FENC) announced a $12.5 million senior loan with the Life Sciences Group at Bridge Bank. The loan will have a maturity date of October 1, … Continue Reading
Read NowInsights - Today, Aldeyra (ALDX) acquired privately company Helio Vision for an all stock deal worth $12.5M, with milestones of up to additional $12.5M. The acquisition adds yet … Continue Reading
Read NowInsights - SBPH is developing inarigivir, an immune activator that boosts the efficacy of the immune system fighting off Hepatitis B. Spring Bank’s candidate has the potential … Continue Reading
Member: Read Now
